繁体中文
设为首页
加入收藏
当前位置:药品说明书与价格首页 >> 抗感染类 >> 新药推荐 >> Kerydin(Tavaborole Topical Solution, 5%)

Kerydin(Tavaborole Topical Solution, 5%)

2015-05-17 17:08:50  作者:新特药房  来源:互联网  浏览次数:116  文字大小:【】【】【
简介: KERYDIN 5%外用溶液获FDA批准为局部治疗甲真菌感染新药2014年7月7日,美国FDA批准Kerydin(5% Tavaborole溶液)用于局部治疗趾甲真菌感染。Tavaborole是首个用于治疗趾甲感染的氧硼戊环(oxaborole)类 ...

KERYDIN 5%外用溶液获FDA批准为局部治疗甲真菌感染新药
2014年7月7日,美国FDA批准Kerydin(5% Tavaborole溶液)用于局部治疗趾甲真菌感染。
Tavaborole是首个用于治疗趾甲感染的氧硼戊环(oxaborole)类抗真菌药物,Anacor专注于基于硼元素的药物的研发和生产,根据其最新的消息,Tavaborole未来也可用于手指甲感染。
该药物是FDA在一个月内批准的第二个局部治疗趾甲真菌感染的药物,其在6月6日批准了Valeant 旗下Jublia(10% Efinaconazole溶液)的上市申请。
Tavaborole的适应证为红色毛癣菌或须毛癣菌引起的趾甲真菌感染。说明书推荐每日一次用于感染的趾甲,疗程共48周,根据Anacor的建议,不需要进行趾甲清创术。
FDA是基于2项共纳入1194例患者的多中心、随机、双盲临床试验确定Tavaborole的有效性和安全性的。
临床试验将Tavaborole与含有活性护肤品成分的局部赋形剂相对比。主要终点为“完全治愈“,定义为趾甲完全干净(0%的临床病变),同时KOH测试及培养阴性确定真菌感染治愈。
在两个试验中,完全治愈的比例分别6.5%和9.1%,各自使用赋形剂的对照组完全治愈的比例为0.5和1.5%。
次要终点为“完全或接近完全治愈”,即真菌感染治愈的同时临床病变小于10%,或者仅有真菌感染的治愈。在这两方面Tavaborole均表现出明显优势
Tabavorole商品名Kerydin,由Anacor Pharmaceuticals研发。


HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use KERYDIN safely and effectively. See full prescribing information for KERYDIN.
KERYDIN ®(tavaborole)topical solution, 5%
INITIAL U.S. APPROVAL: 2014
INDICATIONS AND USAGE
KERYDIN is an oxaborole antifungal indicated for the topical treatment of onychomycosis of the toenails due to Trichophyton rubrum or Trichophyton mentagrophytes. (1)
DOSAGE AND ADMINISTRATION
Apply KERYDIN to affected toenails once daily for 48 weeks. (2)
KERYDIN should be applied to the entire toenail surface and under the tip of each toenail being treated. (2)
For topical use only. (2)
Not for oral, ophthalmic, or intravaginal use. (2)
DOSAGE FORMS AND STRENGTHS
Solution, 5%. (3)
CONTRAINDICATIONS
None. (4)
ADVERSE REACTIONS
Common adverse reactions occurring in ≥1% in subjects treated with KERYDIN included application site exfoliation, ingrown toenail, application site erythema, and application site dermatitis. (6.1)
To report SUSPECTED ADVERSE REACTIONS, contact Anacor Pharmaceuticals at 1-844-4ANACOR [1-844-426-2267] or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.
Revised: 3/2015
FULL PRESCRIBING INFORMATION: CONTENTS*
1 INDICATIONS AND USAGE
KERYDIN (tavaborole) topical solution, 5% is an oxaborole antifungal indicated for the treatment of onychomycosis of the toenails due to Trichophyton rubrum or Trichophyton mentagrophytes. 
2 DOSAGE AND ADMINISTRATION
Apply KERYDIN to affected toenails once daily for 48 weeks.
KERYDIN should be applied to the entire toenail surface and under the tip of each toenail being treated.
KERYDIN is for topical use only and not for oral, ophthalmic, or intravaginal use.
3 DOSAGE FORMS AND STRENGTHS
KERYDIN topical solution, 5% is a clear, colorless alcohol-based solution. Each milliliter of solution contains 43.5 mg (5% w/w) of tavaborole.
4 CONTRAINDICATIONS
None.
6 ADVERSE REACTIONS
6.1 Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
In two clinical trials, 791 subjects were treated with KERYDIN. The most commonly reported adverse reactions are listed below (Table 1).
Table 1: Adverse Reactions Occurring in ≥1% of KERYDIN Topical Solution, 5%-Treated Subjects and at a Greater Frequency than Observed with Vehicle 

Preferred Term KERYDIN
N=791

n(%)
Vehicle
N=395

n(%)
Application site exfoliation 21 (2.7%) 1 (0.3%)
Ingrown toenail 20 (2.5%) 1 (0.3%)
Application site erythema 13 (1.6%) 0 (0%)
Application site dermatitis 10 (1.3%) 0 (0%)
A cumulative irritancy study revealed the potential for KERYDIN to cause skin irritation. There was no evidence that KERYDIN causes contact sensitization.
7 DRUG INTERACTIONS
In vitro studies have shown that tavaborole, at therapeutic concentrations, neither inhibits nor induces cytochrome P450 (CYP450) enzymes.
8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
Pregnancy Category C
There are no adequate and well-controlled studies with KERYDIN in pregnant women. KERYDIN should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Systemic embryofetal development studies were conducted in rats and rabbits and a dermal embryofetal development study was conducted in rabbits.
Oral administration:
In an oral embryofetal development study in rats, oral doses of 30, 100, and 300 mg/kg/day tavaborole were administered during the period of organogenesis (gestational days 6-19) to pregnant female rats. In the presence of maternal toxicity, embryofetal toxicity (increased embryofetal resorption and/or deaths) and drug-related skeletal malformations and variations suggestive of delayed development (i.e., a delay in ossification) were noted in fetuses at 300 mg/kg/day tavaborole [570 times the Maximum Recommended Human Dose (MRHD) based on Area Under the Curve (AUC) comparisons]. No developmental toxicity was noted in rats at 100 mg/kg/day tavaborole (26 times the MRHD based on AUC comparisons).
In an oral embryofetal development study in rabbits, oral doses of 15, 50, and 150 mg/kg/day tavaborole were administered during the period of organogenesis (gestational days 7-19) to pregnant female rabbits. In the presence of maternal toxicity, excessive embryofetal mortality due to post-implantation loss was noted at 150 mg/kg/day tavaborole. No drug related malformations were noted in rabbits at 150 mg/kg/day tavaborole (155 times the MRHD based on AUC comparisons). No embryofetal mortality was noted in rabbits at 50 mg/kg/day tavaborole (16 times the MRHD based on AUC comparisons).
Topical administration:
In a dermal embryofetal development study in rabbits, topical doses of 1%, 5%, and 10% tavaborole solution were administered during the period of organogenesis (gestational days 6-28) to pregnant female rabbits. A dose dependent increase in dermal irritation at the treatment site was noted at 5% and 10% tavaborole solution. A decrease in fetal bodyweight was noted at 10% tavaborole solution. No drug related malformations were noted in rabbits at 10% tavaborole solution (36 times the MRHD based on AUC comparisons). No embryofetal toxicity was noted in rabbits at 5% tavaborole solution (26 times the MRHD based on AUC comparisons).
Nonteratogenic effects:
In an oral pre- and post-natal development study in rats, oral doses of 15, 60, and 100 mg/kg/day tavaborole were administered from the beginning of organogenesis (gestation day 6) through the end of lactation (lactation day 20). In the presence of minimal maternal toxicity, no embryofetal toxicity or effects on postnatal development were noted at 100 mg/kg/day (29 times the MRHD based on AUC comparisons).
8.3 Nursing Mothers
It is not known whether tavaborole is excreted in human milk following topical application of KERYDIN. Because many drugs are excreted in human milk, caution should be exercised when KERYDIN is administered to a nursing woman.
8.4 Pediatric Use
Safety and effectiveness in pediatric patients have not been established.
8.5 Geriatric Use
In clinical trials of 791 subjects who were exposed to KERYDIN, 19% were 65 years of age and over, while 4% were 75 years of age and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, but greater sensitivity of some older individuals cannot be ruled out.
11 DESCRIPTION
KERYDIN (tavaborole) topical solution, 5% contains tavaborole, 5% (w/w) in a clear, colorless alcohol-based solution for topical use. The active ingredient, tavaborole, is an oxaborole antifungal with the chemical name of 5-fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole. The chemical formula is C7H6BFO2, the molecular weight is 151.93 and the structural formula is:


Tavaborole is a white to off-white powder. It is slightly soluble in water and freely soluble in ethanol and propylene glycol.
Each mL of KERYDIN contains 43.5 mg of tavaborole. Inactive ingredients include alcohol, edetate calcium disodium, and propylene glycol.
12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
KERYDIN is an oxaborole antifungal [see Clinical Pharmacology (12.4)].
12.2 Pharmacodynamics
At therapeutic doses, KERYDIN is not expected to prolong QTc to any clinically relevant extent.
12.3 Pharmacokinetics
Tavaborole undergoes extensive metabolism. Renal excretion is the major route of elimination.
In a clinical pharmacology trial of six healthy adult male volunteers who received a single topical application of 5% 14C-tavaborole solution, tavaborole conjugates and metabolites were shown to be excreted primarily in the urine.
The pharmacokinetics of tavaborole was investigated in 24 subjects with distal subungual onychomycosis involving at least 4 toenails (including at least 1 great toenail) following a single dose and a 2-week daily topical application of 200 μL of a 5% solution of tavaborole to all ten toenails and 2 mm of skin surrounding each toenail. Steady state was achieved after 14 days of dosing. After a single dose, the mean (± standard deviation) peak concentration (Cmax) of tavaborole was 3.54 ± 2.26 ng/mL (n=21 with measurable concentrations, range 0.618-10.2 ng/mL, LLOQ=0.5 ng/mL), and the mean AUClast was 44.4 ± 25.5 ng*hr/mL (n=21). After 2 weeks of daily dosing, the mean Cmax was 5.17 ± 3.47 ng/mL (n=24, range 1.51-12.8 ng/mL), and the mean AUCτ was 75.8 ± 44.5 ng*hr/mL.
12.4 Microbiology
Mechanism of Action
The mechanism of action of tavaborole is inhibition of fungal protein synthesis. Tavaborole inhibits protein synthesis by inhibition of an aminoacyl-transfer ribonucleic acid (tRNA) synthetase (AARS).
Activity in vitro and in clinical infections
Tavaborole has been shown to be active against most strains of the following microorganisms, both in vitro and in clinical infections [see Indications and Usage (1)]:
Trichophyton rubrum
Trichophyton mentagrophytes
Mechanism of Resistance
Trichophyton mentagrophytes and Trichophyton rubrum strains from isolates collected in the clinical trials have not demonstrated resistance following repeated exposure to tavaborole.
13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
In an oral carcinogenicity study in Sprague-Dawley rats, oral doses of 12.5, 25, and 50 mg/kg/day tavaborole were administered to rats once daily for 104 weeks. No drug related neoplastic findings were noted at oral doses up to 50 mg/kg/day tavaborole (14 times the MRHD based on AUC comparisons).
In a dermal carcinogenicity study in CD-1 mice, topical doses of 5%, 10%, and 15% tavaborole solution were administered to mice once daily for 104 weeks. No drug related neoplastic findings were noted at topical doses up to 15% tavaborole solution (89 times the MRHD based on AUC comparisons).
Tavaborole revealed no evidence of mutagenic or clastogenic potential based on the results of two in vitro genotoxicity tests (Ames assay and Human lymphocyte chromosomal aberration assay) and one in vivo genotoxicity test (rat micronucleus assay).
No effects on fertility were observed in male and female rats that were administered oral doses up to 300 mg/kg/day tavaborole (107 times the MRHD based on AUC comparisons) prior to and during early pregnancy.
14 CLINICAL STUDIES
The efficacy and safety of KERYDIN was evaluated in two multicenter, double-blind, randomized, vehicle-controlled trials. KERYDIN or vehicle was applied once daily for 48 weeks in subjects with 20% to 60% clinical involvement of the target toenail, without dermatophytomas or lunula (matrix) involvement.
A total of 1194 subjects (795 KERYDIN, 399 Vehicle) 18 to 88 years of age, 82% male, 84% white, participated in these two trials. Efficacy assessments were made at 52 weeks following a 48-week treatment period.
The Complete Cure efficacy endpoint included negative mycology (negative KOH wet mount and negative fungal culture) and Completely Clear Nail (no clinical evidence of onychomycosis as evidenced by a normal toenail plate, no onycholysis, and no subungual hyperkeratosis). Efficacy results from the two trials are summarized in Table 2.
Table 2: Efficacy Outcomes 

Efficacy Variable Trial 1 Trial 2
KERYDIN
N=399

n(%)
Vehicle
N=194

n(%)
KERYDIN
N=396

n(%)
Vehicle
N=205

n(%)
Complete Curea 26 (6.5%) 1 (0.5%) 36 (9.1%) 3 (1.5%)
Complete or Almost Complete Cureb 61 (15.3%) 3 (1.5%) 71 (17.9%) 8 (3.9%)
Mycologic Curec 124 (31.1%) 14 (7.2%) 142 (35.9%) 25 (12.2%)

a. Complete cure defined as 0% clinical involvement of the target toenail plus negative KOH and negative culture.
b. Complete or almost complete cure defined as ≤10% affected target toenail area involved and negative KOH and culture.
c. Mycologic cure defined as negative KOH and negative culture.
16 HOW SUPPLIED/STORAGE AND HANDLING
16.1 How Supplied KERYDIN (tavaborole) topical solution, 5% is a clear, colorless solution supplied in an amber glass bottle with a screw cap. At initial use, the screw cap is replaced with the dropper assembly.
KERYDIN (tavaborole) topical solution, 5% is supplied in the following presentations:
NDC 10337-905-10: One bottle containing 10 mL of solution with one glass pointed-tip dropper.
NDC 10337-905-44: One bottle containing 4 mL of solution with one glass pointed-tip dropper.
16.2 Storage and Handling Store at 20–25°C (68–77°F); excursions permitted to 15–30°C (59–86°F) [see USP Controlled Room Temperature].
CAUTION: Flammable. Keep away from heat and flame.
Discard product within 3 months after insertion of the dropper.
Keep bottle tightly closed. Keep out of reach of children.

责任编辑:admin


相关文章
OXISTAT Lotion(硝酸奥昔康唑洗液1%)
OXISTAT Cream(硝酸奥昔康唑软膏1%)
KERYDIN(5%, tavaborole)外用溶液
注射用米卡芬净粉剂(MICAFUNGIN SODIUM,Fungard)
阿尼芬净注射液ERAXIS(ANIDULAFUNGIN)
大扶康胶囊
丁克(盐酸特比萘芬软膏)
兰美抒片剂
达克宁散
得凡尼金
 

最新文章

更多

· FOSMICIN-S FOR INJECTI...
· LINEZOLID INJECTION(利...
· 硫酸卡那霉素注射剂(Ka...
· 注射用米诺环素|MINOCIN...
· Cresemba(isavuconazoni...
· Kerydin(Tavaborole Top...
· Avelox(盐酸莫西沙星片和...
· Avelox(moxifloxacin H...
· 迪拉马尼片|DELTYBA(De...
· CRESEMBA(艾沙康唑硫酸酯...

推荐文章

更多

· FOSMICIN-S FOR INJECTI...
· LINEZOLID INJECTION(利...
· 硫酸卡那霉素注射剂(Ka...
· 注射用米诺环素|MINOCIN...
· Cresemba(isavuconazoni...
· Kerydin(Tavaborole Top...
· Avelox(盐酸莫西沙星片和...
· Avelox(moxifloxacin H...
· 迪拉马尼片|DELTYBA(De...
· CRESEMBA(艾沙康唑硫酸酯...

热点文章

更多